Alogliptin
- Generic Name
- Alogliptin
- Brand Names
- Incresync, Kazano, Nesina, Oseni, Vipidia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N5O2
- CAS Number
- 850649-61-5
- Unique Ingredient Identifier
- JHC049LO86
- Background
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
- Indication
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 82
- Registration Number
- NCT00763347
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 265
- Registration Number
- NCT00755846
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 441
- Registration Number
- NCT00707993
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 71
- Registration Number
- NCT00655863
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 803
- Registration Number
- NCT00432276
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2013-03-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 655
- Registration Number
- NCT00395512
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1554
- Registration Number
- NCT00328627
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3323
- Registration Number
- NCT00306384
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 329
- Registration Number
- NCT00286455
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath